[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ascendis Pharma ADR (ASND)

Ascendis Pharma ADR (ASND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Ascendis Pharma's Second Profitable Quarter: Proof of Concept or Accounting Artifact?

Ascendis Pharma A/S (ASND) reports second-quarter 2026 earnings before market open on August 13, with analysts expecting the biotechnology company to deliver $0.78 per share on revenue of approximately $377 million. The central question is whether ASND can sustain its recent profitability momentum after posting its first positive quarterly earnings in Q1 2026, while investors watch for updates on the commercial trajectory of its key growth drivers YORVIPATH and SKYTROFA. This report comes at a pivotal moment as the company transitions from development-stage losses to sustained profitability.

Ascendis Pharma is a biopharmaceutical company focused on developing and commercializing endocrine rare disease therapies using its...

Fundamentals

See More
  • Market Capitalization, $K 15,359,086
  • Shares Outstanding, K 62,377
  • Annual Sales, $ 814,760 K
  • Annual Income, $ -258,000 K
  • EBIT $ -15 M
  • EBITDA $ 5 M
  • 60-Month Beta 0.39
  • Price/Sales 19.56
  • Price/Cash Flow N/A
  • Price/Book 27.80

Options Overview Details

View History
  • Implied Volatility 43.27% (-5.39%)
  • Historical Volatility 28.16%
  • IV Percentile 22%
  • IV Rank 32.05%
  • IV High 65.95% on 01/07/26
  • IV Low 32.57% on 05/12/26
  • Expected Move (DTE 7) 11.24 (4.56%)
  • Put/Call Vol Ratio 1.94
  • Today's Volume 471
  • Volume Avg (30-Day) 221
  • Put/Call OI Ratio 0.30
  • Today's Open Interest 12,134
  • Open Int (30-Day) 12,064
  • Expected Range 234.99 to 257.47

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $1.21
  • Number of Estimates 8
  • High Estimate $1.64
  • Low Estimate $0.59
  • Prior Year $-1.17
  • Growth Rate Est. (year over year) +203.42%

Price Performance

See More
Period Period Low Period High Performance
1-Month
239.56 +2.78%
on 08/04/26
268.77 -8.39%
on 07/15/26
-18.99 (-7.16%)
since 07/13/26
3-Month
203.80 +20.82%
on 06/08/26
282.15 -12.73%
on 07/09/26
+2.65 (+1.09%)
since 05/13/26
52-Week
186.05 +32.34%
on 10/20/25
282.15 -12.73%
on 07/09/26
+55.15 (+28.86%)
since 08/13/25

Most Recent Stories

More News
Ascendis Pharma Reports Second Quarter 2026 Financial Results

– Q2 2026 product revenue of €315 million (+105% Y/Y), comprising €252 million for YORVIPATH ® , €55 million for SKYTROFA ® , and €8 million for YUVIWEL ® – Through July...

ASND : 246.23 (-3.61%)
Ascendis Pharma's Second Profitable Quarter: Proof of Concept or Accounting Artifact?

Barchart Research What to Expect from ASND Earnings ASND Generated August 12, 2026 Current Price $255.46 EPS Estimate $$0.78 Consensus Rating Strong Buy Average Move 4.70% Ascendis Pharma's Second Profitable...

ASND : 246.23 (-3.61%)
Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026

COPENHAGEN, Denmark, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report second quarter 2026 financial results and provide a business update on Thursday,...

ASND : 246.23 (-3.61%)
Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.

TransCon ® CNP and TransCon hGH combination therapy Week 78 data from the Phase 2 COACH Trial showed durable, unprecedented increase in healthy, proportional growth TransCon CNP monotherapy Week...

ASND : 246.23 (-3.61%)
Ascendis Pharma's First Earnings as an Ordinary Share Won't Clarify What Changed

Barchart Research What to Expect from ASND Earnings ASND Generated August 5, 2026 Current Price $244.20 EPS Estimate $$1.29 Consensus Rating Strong Buy Average Move 4.70% Ascendis Pharma's First Earnings...

ASND : 246.23 (-3.61%)
Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial

Data presented during ICCBH 2026 showed that improvements in tibial-femoral angle (TFA), a measure of lower extremity alignment, continued through Week 104 Greater improvements observed in children...

ASND : 246.23 (-3.61%)
Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap®

COPENHAGEN, Denmark, June 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company has been added to the broad-market Russell 3000 ® Index, the large-cap Russell...

ASND : 246.23 (-3.61%)
Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026

COPENHAGEN, Denmark, June 25, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its clinical development programs for the treatment of children with...

ASND : 246.23 (-3.61%)
Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism

Multi-organ system and quality-of-life benefits sustained through three and a half years  86% response rate for the multi-component endpoint 89% of patients completed the three-and-a-half-year...

ASND : 246.23 (-3.61%)
5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism

– Multi-organ system and quality-of-life benefits sustained through five years of treatment – 82% response rate for the multi-component endpoint – 95% of patients completed five years...

ASND : 246.23 (-3.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Ascendis Pharma A/S is a biopharmaceutical company. The company's product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology,...

See More

Key Turning Points

3rd Resistance Point 257.71
2nd Resistance Point 254.57
1st Resistance Point 250.40
Last Price 246.23
1st Support Level 243.09
2nd Support Level 239.95
3rd Support Level 235.78

See More

52-Week High 282.15
Last Price 246.23
Fibonacci 61.8% 245.44
Fibonacci 50% 234.10
Fibonacci 38.2% 222.76
52-Week Low 186.05

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.